An Expanded Portfolio of Survival Metrics for Assessing Anticancer Agents
A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
The Utility of Cost Discussions Between Patients With Cancer and Oncologists
Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs-usually without altering treatment.
2 Clarke Drive Cranbury, NJ 08512